* Warnings in the labeling of all fluoroquinolone antibiotics have been strengthened to more effectively alert providers to the risk of peripheral neuropathy with systemic use of these drugs.
* Topical preparations for the eye and ear don't share this risk.
* Peripheral neuropathy can result quickly after initiating therapy with a fluoroquinolone and can be permanent.
Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org.